ReviewOncotarget2018
Stromal cells in breast cancer as a potential therapeutic target.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.La Radiologia medica · 2026Article
- Reliability of stromal markers multiplex immunofluorescent staining: pathologist assessment compared to quantitative image analysis.American journal of cancer research · 2026Article
- Hypoxia-inducible factors in breast cancer: prognostic indicators and emerging biomarkers: narrative review.Annals of medicine and surgery (2012) · 2025Review
- The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review.Virchows Archiv : an international journal of pathology · 2025Review
- Exploring the interaction between extracellular matrix components in a 3D organoid disease model to replicate the pathophysiology of breast cancer.Journal of experimental & clinical cancer research : CR · 2023Review
- Stromal cells in the tumor microenvironment: accomplices of tumor progression?Cell death & disease · 2023Review
- Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacy.Drug delivery and translational research · 2023Article
- Integrated analysis of 1804 samples of six centers to construct and validate a robust immune-related prognostic signature associated with stromal cell abundance in tumor microenvironment for gastric cancer.World journal of surgical oncology · 2022Article
- Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression.Reviews of physiology, biochemistry and pharmacology · 2022Review
- Automatic Multi-functional Integration Program (AMFIP) towards all-optical mechano-electrophysiology interrogation.PloS one · 2022Article
- Article
- Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics.Tissue engineering. Part A · 2021Article
- Chemotherapy resistance and stromal targets in breast cancer treatment: a review.Molecular biology reports · 2020Review
- Review
- Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer.Cancer medicine · 2019Article
- Immunotherapy: breaching the barriers for cancer treatment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- Axl signaling is an important mediator of tumor angiogenesis.Oncotarget · 2019Article
- Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment.Processes (Basel, Switzerland) · 2019Article
- MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer in the United States is the second most commonly diagnosed cancer in women. About 1 in 8 women will develop invasive breast cancer over the course of her lifetime and breast cancer remains the second leading cause of cancer-related death. In pursuit of novel therapeutic strategies, researchers have examined the tumor microenvironment as a potential anti-cancer target. In addition to neoplastic cells, the tumor microenvironment is composed of several critical normal cell types, including fibroblasts, vascular and lymph endothelial cells, osteoclasts, adipocytes, and immune cells. These cells have important roles in healthy tissue stasis, which frequently are altered in tumors. Indeed, tumor-associated stromal cells often contribute to tumorigenesis, tumor progression, and metastasis. Consequently, these host cells may serve as a possible target in anti-tumor and anti-metastatic therapeutic strategies. Targeting the tumor associated host cells offers the benefit that such cells do not mutate and develop resistance in response to treatment, a major cause of failure in cancer therapeutics targeting neoplastic cells. This review discusses the role of host cells in the tumor microenvironment during tumorigenesis, progression, and metastasis, and provides an overview of recent developments in targeting these cell populations to enhance cancer therapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.